Clinical trial · Observational
Use of a Liquid Biopsy Signature to Detect Early-onset Gastric Cancer
Use of a Liquid Biopsy Signature as Blood Biomarker for Early Detection and Monitoring Early-onset Gastric Cancer
NCT06023121CI-TRIAL-00069298completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Early-onset gastric cancer (EOGC) is a lethal malignancy with a poor prognosis. It differs from late-onset gastric cancer (LOGC) in clinical and molecular characteristics. The current strategies for EOGC detection have certain limitations in diagnostic performance due to the rising trend in EOGC. Hence, identifying novel EOGC bioindicators is crucial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Measurement of levels of an exosome-based liquid biopsy signature | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cases
- description
- Gastric cancer cases from two medical centers in China
- interventionNames
- Diagnostic Test: Measurement of levels of an exosome-based liquid biopsy signature
- label
- Controls
- description
- Controls from two medical centers in China
- interventionNames
- Diagnostic Test: Measurement of levels of an exosome-based liquid biopsy signature
Primary outcomes (1)
- measure
- Detection of levels of an exosome-based liquid biopsy signature
- timeFrame
- Through study completion, an average of 3 year
- description
- A three exo-LR (NALT1, PTENP1, and HOTTIP) liquid biopsy signature was developed for EOGC detection.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Having signed informed consent * 50 years old ≥ Age ≥ 18 years old * Histologically confirmed gastric adenocarcinoma Exclusion Criteria: * Other previous malignancy within 5 year * Surgery (excluding diagnostic biopsy) within 4 weeks prior to study * Pregnancy or lactation period * Legal incapacity
References
Publications (0)
Data not yet available
No reference posted for this study.